ARROWHEAD PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY September 30, 2025 | FY September 30, 2024 | FY September 30, 2023 | FY September 30, 2022 | FY September 30, 2021 |
|---|---|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M | $243.2M | $138.3M |
| Operating income | $98.3M | -$601.1M | -$205.0M | -$178.5M | -$149.0M |
| Operating expenses | $731.1M | $604.6M | $445.7M | $421.7M | $287.3M |
| Cash from operations | $179.6M | -$462.9M | -$153.9M | -$136.1M | $171.3M |
| Capital expenditure | $22.7M | $141.5M | $176.7M | $52.8M | $23.6M |
| Free cash flow | $156.9M | -$604.3M | -$330.6M | -$188.9M | $147.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.4B | $1.1B | $765.6M | $691.9M | $710.1M |
Shares outstanding 140.9M · Free float 91.3%
Annual filing data through FY ended September 30, 2025; float as of July 11, 2026.